SPOTLIGHT: Developers pull European Dacogen application
MGI Pharma and SuperGen have pulled their European application for Dacogen injection saying they will need to provide more clinical data. But the companies added that the decision won't have an impact on their US application and have submitted their response to the FDA's approvable letter. Release
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
